Antiviral compounds
AssigneeGilead Sciences, Inc.
InventorsJohn O. Link, Jeromy J. Cottell, Teresa Alejandra Trejo Martin, Elizabeth M. Bacon
Life of this patent
Estimating the term…
Abstract
The disclosure is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
Claims55
A compound of formula (I):
- E1a-V1a—C(═O)—P1a—W1a—P1b—C(═O)—V1b-E1b (I)
- wherein:
- W1a is
- and W1a is optionally substituted with one or more halo, alkyl, haloalkyl, optionally substituted aryl, optionally substituted heterocycle, or cyano;
- Y5 is —O—CH2—, —CH2—O—, —O—C(═O)—, or —C(═O)—O—;
- X5 is —CH2—CH2—, or —CH═CH—;
- P1a and P1b are each independently:
- V1a and V1b are each independently:
- provided that at least one of V1a and V1b is
- E1a and E1b are each independently —N(H)(alkoxycarbonyl), —N(H)(cycloalkylcarbonyl), or —N(H)(cycloalkyloxycarbonyl);
- or E1a-V1a taken together are R9a;
- or E1b-V1b taken together are R9b;
- and
- R9a and R9b are each independently:
- or a pharmaceutically acceptable salt or prodrug thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt or prodrug thereof.
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt or prodrug thereof.
A compound having the formula:
A compound having the formula:
A pharmaceutical composition comprising the compound as described in any preceding claim or a pharmaceutically acceptable salt, or prodrug thereof;
- and at least one pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.